glaxosmithkline pharma (Emkay) Steady business momentum; Maintain Hold

Revenue growth led by traction across business units; EBITDA margins contraction led by higher raw material and other expenses; One-time provisioning dented bottom-line
Date Rating Target Price Recommendation Price Broker house
6 May 2011 hold 2161 2288 Emkay Report

No comments:

Post a Comment